SunWay Biotech and Gnosis by Lesaffre Form Alliance to Launch MenaQ7® Metabolic, featuring the ANKASCIN® 568-R ingredient

SunWay and Gnosis by Lesaffre Form Alliance

California, USA, March 14, 2024 – SunWay Biotech, a leading ingredients manufacturer and Gnosis by Lesaffre, a fermentation solutions provider, has today announced a strategic partnership to launch their inaugural product, MenaQ7® Metabolic, featuring the ANKASCIN® 568-R ingredient.

Announcing their alliance and unveiling their new product at the Natural Products Expo West, the product is aimed at the $2 Billion Global vitamin K2 market. The new product launch marks the beginning of a deeper collaboration in product development and international supply chain integration between the two leading nutraceutical experts.

MenaQ7® Metabolic combines two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R. MenaQ7® is the only Vitamin K2 as MK-7 clinically proven beneficial for bone and heart health, offering the highest quality assurance. ANKASCIN® 568-R is the world’s only red yeast rice fermentation material without Monacolin K (Statin). SunWay Biotech, invited by the US Pharmacopeial Convention (USP), contributed to the development of a red yeast rice health product chapter, and ANKASCIN® 568-R has obtained New Dietary Ingredient (NDI) status. With over 130 scientific publications, ANKASCIN® 568-R has been recognized for its benefits in addressing various metabolic issues and received the Nutraingredient Asia Awards.

John Pan, General Manager of Sunway Biotech, commented: “Sunway Biotech is committed to enhancing human health through advanced biological transformation processes. By leveraging unique fermentation technology, SunWay maximizes the commercial value of natural functional ingredients and maintains its industry-leading position through continuous expansion of its strain library and optimization of fermentation core technology. We are honored to partner with Gnosis by Lesaffre, a key global player in fermentation. Sunway looks forward to supporting quality and unique ingredients to global nutraceuticals.”

SunWay Biotech and Gnosis by Lesaffre aim to expand globally by leveraging this collaboration to drive more product innovation to tackle some of the world’s most prevalent health issues.


About Sunway Biotech:
Founded in 2007, SunWay Biotech Co., Ltd. (Stock Code: 1271) is a leading producer of health food ingredients. With a focus on high-quality red yeast rice and probiotic raw materials, the company has gained global recognition, securing patents in key markets such as the US, Canada, EU, China, Japan, South Korea, and Taiwan. Through innovative integration into health and nutrition products, SunWay Biotech caters to the evolving needs of modern consumers, offering diverse and effective wellness solutions. Contact us for more information.

About Gnosis by Lesaffre:
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and well-being. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
Gnosis by Lesaffre – Exploring Life to Improve Living.

About Lesaffre:
A key global player in fermentation for more than a century, Lesaffre, with a 2.7 billion euro turnover, and established on all continents, counts 11,000 employees and more than 90 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms. To nourish 9 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe that fermentation is one of the most promising answers to this challenge.
Lesaffre – Working together to better nourish and protect the planet.

Please share this content with others who may benefit from it.
You may also be interested in
Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith  for $210 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc. (“Upsher-Smith”), a generics manufacturer based in Minnesota, US, from shareholders, Sawai Group Holdings Co., Ltd. (JP), and Sumitomo Corporation of Americas, for a total consideration of up to US$210 million.